Milan, March 31 (beraking latest news Health) – “At the moment the” ongoing safety review of AstraZeneca’s anti-Covid vaccine “has not identified any specific risk factors, such as age, gender or a previous medical history of bleeding disorders”, for “very rare events” of abnormal thrombosis reported after administration of the product. This was reported by the European Medicines Agency EMA, informing that the Prac Pharmacovigilance Committee meets today as part of the review on these “very rare episodes of unusual thrombosis associated with a low number of platelets, in people vaccinated with Vaxzevria”.
“On Monday, March 29, the EMA convened a meeting of the” set up “ad hoc group of experts to provide further contributions to the ongoing assessment – reminds the EU regulatory body – Independent external experts”, belonging to a wide “range of specialties Physicians, including hematologists, neurologists and epidemiologists, have discussed specific aspects such as possible mechanisms “of these rare thromboses,” whether underlying risk factors can be identified, and what additional data are needed to further characterize the observed events and potential risk. the result of this meeting will be discussed by the PRAC and will contribute to the ongoing evaluation “.
COPYRIGHT today © breaking latest news